Prof. Francesca Levi-Schaffer, PharmD, PhD
Francesca Levi-Schaffer is a member of the Board of Directors and Treasurer of the World Allergy Organization (WAO). She is a Professor at The Hebrew University of Jerusalem (HUJI) in the Institute for Drug Research of the School of Pharmacy, Faculty of Medicine. She holds the Isaac and Myrna Kaye Chair in Immunopharmacology. From 2006-2009, Prof. Levi-Schaffer was Chair of the Department of Pharmacology and Experimental Therapeutics and head of the Teaching Unit of Pharmacology and Experimental Therapeutics in the HUJI Faculty of Medicine, School of Pharmacy. Prof. Levi-Schaffer was born in Italy and completed her PharmD degree at the University of Milano. In 1984, she received her PhD degree in Immunology from the Weizmann Institute, Rehovot, Israel. Her post-doctoral training was at Harvard Medical School (1984-86).
Prof. Levi-Schaffer has published 154 articles in peer-reviewed journals, 72 reviews and editorials and 25 book chapters. She has one patent and two provisional patents pending. In 2011, she was elected Chairperson of the National Committee of the International Union of Pharmacology (IUPHAR) representing the Israel Academy of Sciences and Humanities. In 2012, she was instrumental in the establishment of an Immunopharmacology Section in the IUPHAR and serves as its first Chairperson. She is a member of the Israeli Ministry of Health Committee for Human Experimentation of New Drugs, a Councilor and member of the Executive Committee of the International Union of Basic and Clinical Pharmacology (IUPHAR), an Associate Editor for the journal Pharmacological Research, a Council member of the Collegium Internationale Allergologicum (CIA), and a member of the management committee of COST Action 1201 Developmental Origins of Chronic Lung Disease.
Prof. Levi-Schaffer's expertise is in the area of immunopharmacology of allergy focusing on mast cell and eosinophil cross-talk (AEU) in allergy, mast cells and surface inhibitory and activating receptors; the role of mast cells and eosinophils in hypoxia (allergy, COPD); mastocytosis treatment; atopic dermatitis, the microbiome and the AEU; and bispecific antibodies as novel drugs for allergy.